Retatrutide is an experimental drug developed to treat obesity and potentially T2D. It’s a triple agonist that targets glucagon-like peptide-1, glucagon, and gastric inhibitory polypeptide receptors. In clinical trials, retatrutide has shown dose-dependent weight loss, with some participants losing up to 24% of their body weight after 48d weeks.